Laura Morrison
Education
M.Sc., public health, McGill University; H.B.A., business administration, Ivey Business School at Western University
Summary of Experience
Ms. Morrison specializes in economic modeling and health economics and outcomes research. She has worked on several retrospective observational studies using claims databases, as well as cost-effectiveness analyses. Ms. Morrison has experience in disease areas such as oncology, coronary artery disease, major depressive disorder, psoriatic arthritis, and schizophrenia. Her research has been presented at numerous international conferences, and she is the author of several scientific articles in peer-reviewed journals such as the Journal of Medical Economics, Current Medical Research and Opinion, Clinical Therapeutics, and the Journal of Managed Care & Specialty Pharmacy. Prior to joining Analysis Group, Ms. Morrison worked as the research coordinator for a $25 million pan-Canadian youth mental health research project that aimed to reduce wait times and improve access to appropriate mental health services. She was responsible for the design of cost-effectiveness analyses, the development and implementation of an online data collection tool, and the development and delivery of training programs.
-
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Journal of Medical Economics, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, Lefebvre P, Pilon D, George DJ
-
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer
Journal of medical economics, 2024
2024Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Lefebvre P, He A, Vanderpoel J
-
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Journal of Medical Economics, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George D
-
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States
Journal of Managed Care & Specialty Pharmacy, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, Pilon D, George DJ
-
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer
The Oncologist, 2024
2024Bilen MA, Khilfeh I, Rossi C, Morrison L, Diaz L, Hilts A, Lefebvre P, Pilon D, George DJ
-
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
Drugs - Real World Outcomes, 2024
2024Walsh JA, Lin I, Zhao R, Shiff NJ, Morrison L, Emond B, Yu LH, Schwartzbein S, Lefebvre P, Pilon D, Chakravarty SD, Mease P
-
Comparison of Clinical Outcomes in Patients with Schizophrenia Following Different Long-Acting Injectable Event-Driven Initiation Strategies
Schizophrenia, 2023
2023Correll C, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, Morrison L, Ghelerter I, Lefebvre P, Mavros P
-
Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices
Current Oncology, 2023
2023Sheffield BS, Eaton K, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L, Stevens AL, Ewara EM, Cheema P
-
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
Future Oncology, 2023
2023Jacobs R, Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Levy MY
-
Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly, Once-Every-3-Months, and Once-Every-6-Months Paliperidone Palmitate
Journal of Managed Care & Specialty Pharmacy, 2023
2023Morrison L, Lin D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P, Pilon D
-
Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
Patient Preference and Adherence, 2023
2023Lu X, Emond B, Morrison L, Kinkead F, Lefebvre P, Lafeuille MH, Khan W, Wu LH, Qureshi ZP, Jacobs R
-
Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay
Current Medical Research and Opinion, 2023
2023Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C
-
Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States
Journal of Clinical Psychiatry, 2022
2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P
-
Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States
Journal of Affective Disorders, 2022
2022Zhdanava M, Voelker J, Pilon D, Joshi K, Morrison L, Sheehan JJ, Vermette-Laforme M, Lefebvre P, Citrome L
-
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
Journal of Medical Economics, 2022
2022Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, Morrison L
-
Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States
Clinical Therapeutics, 2022
2022Karkare S, Zhdanava M, Pilon D, Nash AI, Morrison L, Shah A, Lefebvre P, Joshi K
-
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
Journal of Medical Economics, 2022
2022Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C
-
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
PharmacoEconomics (2021) 39:707–720
2021Zhdanava M, Voelker J, Pilon D, Cornwall T, Morrison L, Vermette‑Laforme M, Lefebvre P, Nash A, Joshi K, Neslusan C
-
Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
Advances in Therapy, 2021
2021Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder
Current Medical Research and Opinion, 2021
2021Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Prevalence of Potential Drug-Drug Interactions and Pre-existing Conditions for Adverse Events in Augmentation Therapies Among Patients With Treatment-resistant Depression
Psych Congress, 2020
2020Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Use of home health and other healthcare delivery pathways among privately-insured patients with and without treatment-resistant depression
Current Medical Research and Opinion, 2020
2020Pilon D, Szukis H, Singer S, Morrison L, Sheehan JJ, Lefebvre P
-
Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
Journal of Managed Care & Specialty Pharmacy, 2020
2020El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P
-
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans
Current Medical Research and Opinion, January 5, 2019
2019Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K
-
Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Journal of Affective Disorders, 2019
2019Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K
-
The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia
Current Medical Research and Opinion. 2019 Mar;35(3):395-405
2019El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P
-
April 11, 2024
-
January 29, 2024
-
October 23, 2023
-
July 25, 2023
-
June 8, 2023
-
April 12, 2022
-
March 29, 2022
-
June 14, 2021
-
January 21, 2021